Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of human lymphoblastic and myeloblastic leukemia samples with and without MLL rearrangements specific and lineage specific signatures
Gene expression analysis identified a MLL translocation-specific signature of differentially expressed genes discriminating ALL and AML with and without MLL rearrangements. Gene expression signatures of acute lymphoblastic and myeloblastic leukemia samples with and without MLL rearrangements were an...
ORGANISM(S): Homo sapiens 
2009-08-07 | E-GEOD-14062 | biostudies-arrayexpress
TranscriptomicsA Myc transcriptional program that is independent of EMT drives a poor prognosis tumor-propagating phenotype in HER2+ breast cancer
The HER2 (ERBB2) and MYC genes are commonly amplified genes in breast cancer, yet little is known about their molecular and clinical interaction. Using a novel chimeric mammary transgenic approach and in vitro models, we demonstrate markedly increased self renewal and tumour propagating capability o...
ORGANISM(S): Homo sapiens 
2013-09-24 | E-GEOD-43730 | biostudies-arrayexpress
TranscriptomicsRobust Molecular Classification of Ependymal Tumors Across All Anatomic Compartments
Ependymal tumors across age groups have been classified solely by histopathology. It is, however, commonly accepted that this classification has limited clinical utility based on its poor reliability. We aimed at establishing a reliable and reproducible molecular classification using DNA methylation...
ORGANISM(S): Homo sapiens 
2015-05-21 | E-GEOD-65362 | biostudies-arrayexpress
TranscriptomicsThe ets transcription factor ELF5 suppresses the estrogen sensitive phenotype and contributes to antiestrogen resistance in luminal breast cancer. [human]
The ets transcription factor ELF5 specifies the differentiation of mammary progenitor cells to establish the milk-secreting lineage. ER- and poor prognosis basal breast cancers arise from this progenitor cell and these cancers express high levels of Elf5. Knockdown of ELF5 expression in basal breast...
ORGANISM(S): Homo sapiens 
2012-12-27 | E-GEOD-30405 | biostudies-arrayexpress
UnknownManagement of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study.
Not available
S-EPMC7785972 | biostudies-literature
GenomicsThe ets transcription factor ELF5 suppresses the estrogen sensitive phenotype and contributes to antiestrogen resistance in luminal breast cancer. [human ChIP-Seq]
The ets transcription factor ELF5 specifies the differentiation of mammary progenitor cells to establish the milk-secreting lineage. ER- and poor prognosis basal breast cancers arise from this progenitor cell and these cancers express high levels of Elf5. Knockdown of ELF5 expression in basal breast...
ORGANISM(S): Homo sapiens 
2012-12-27 | E-GEOD-31216 | biostudies-arrayexpress
UnknownThe ets transcription factor ELF5 suppresses the estrogen sensitive phenotype and contributes to antiestrogen resistance in luminal breast cancer. [human]
Not available
ORGANISM(S): Homo sapiens 
S-ECPF-GEOD-30405 | biostudies-other
TranscriptomicsThe ets transcription factor ELF5 suppresses the estrogen sensitive phenotype and contributes to antiestrogen resistance in luminal breast cancer. [mouse]
The ets transcription factor ELF5 specifies the differentiation of mammary progenitor cells to establish the milk-secreting lineage. ER- and poor prognosis basal breast cancers arise from this progenitor cell and these cancers express high levels of Elf5. Knockdown of ELF5 expression in basal breast...
ORGANISM(S): Mus musculus 
2014-01-13 | E-GEOD-30406 | biostudies-arrayexpress
GenomicSingle-Cell Analysis of Human Pancreatic Ductal Adenocarcinoma

Cancer-associated fibroblasts (CAFs) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma (PDAC). CAFs constitute a diverse cell population consisting of several recently described subtypes, although the extent of CAF heterogeneity has remained undefined. H...

phs001840 | dbGaP
UnknownThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
Not available
S-EPMC3386495 | biostudies-literature
Sort   by:  
 Page size